Form 8-KOn September 16, 2024, BioReference and Labcorpo consummated the Asset Purchase Agreement pursuant to which BioReference sold to LabCorp cer false

אופקו הלת', אינק	2 380
OPKO HEALTH, INC
Corporation no: 2279206	13156

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	17/09/2024
	www.isa.gov.il			www.tase.co.il				Reference:	2024-02-603726	Time of broadcast: 00:20 00:20

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

Form 8-K On September 16, 2024, BioReference and Labcorpo consummated the Asset Purchase Agreement pursuant to which BioReference sold to LabCorp certain assets and liabilities of BioReference, and the BioReference received approximately $237,500,000 in cash.

20240916_Form_8-K_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: NASDAQ GSM	Date of revision of form structure: 06/08/2024
Address: Ashlegan 16 , Kiryat Gat 8211804   Israel , Tel: 08-9300051 , Fax: 08-9543101
E-mail address: gfaibish@opko.com   Company site: Www.Opko.Com
Previous names of reporting entity:
Name of the Signatory: Faibish Gabriel Position of Signatory in the reporting corporation: General Counsel Name of Employer Company:
Address: Ashlegan 16 , Kiryat Gat 8211804 Telephone: 08-9300051 Facsimile: 08-9543101 E-mail: gfaibish@opko.com 1